JW0201 + C2202 + C2204

**JW0201 + C2202 + C2204** is a pharmaceutical combination investigated as an add-on therapy for patients with type 2 diabetes mellitus who have inadequate glycemic control with C2202 and C2204. In a Phase 3 multicenter, randomized, double-blind, placebo-controlled clinical study, the combination was evaluated for its efficacy in lowering HbA1c over a 24-week treatment period. JW0201 is administered at 200 mg/day, while C2202 is given at ≥1,000 mg/day and C2204 at standard dosing oral administration. The precise mechanisms of action and pharmacological classes of JW0201, C2202, and C2204 are not specified in the available public sources, but they are used in the context of diabetes management as oral agents. The developer and clinical trial sponsor is JW Pharmaceutical[1][3][4].